RecruitingRecruiting
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
NCT06220721 · Medical College of Wisconsin
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
The REPAIR trial is a multicenter randomized controlled trial of 618 postpartum patients with hypertensive disorders of pregnancy randomized to intensive blood pressure control versus usual care during the first 6 weeks postpartum. The intervention group will receive intensive blood pressure (BP) control with nifedipine extended-release initiation when BP is ≥ 140/90 mmHg. The active control group will receive usual care with nifedipine ER initiation when BP is ≥ 150/100. The study will take place at two clinical sites: Medical College of Wisconsin (MCW) and Northwestern University (NU). All participants will undergo BP monitoring, cardiovascular function assessment, and collection of cardiovascular biomarkers at baseline, 6 weeks, and 12 months postpartum. Specifically, cardiac function and structure will be assessed with transthoracic echocardiogram, endothelial dysfunction with brachial artery flow-mediated dilation, and arterial stiffness with carotid-femoral pulse wave velocity. The primary outcome is the incident diagnosis of stage I hypertension at one year postpartum.
Eligibility criteria
Inclusion Criteria:
* Hypertensive disorders of pregnancy (HDP) diagnosis, specifically gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines
* Postpartum day 0-4
* Age ≥ 18 years
* Able to communicate in English or in Spanish
* Has an established OBGYN at an MCW or NU health system practice that has access to Epic electronic medical records.
Exclusion Criteria:
* Pre-gestational hypertension
* Type 1 or type 2 diabetes mellitus
* Admitted to intensive care unit at the time of screening
* Diagnosed with HDP during postpartum readmission after discharge from delivery hospitalization
* Getting discharged on the day of screening
* Known allergy or contraindication to nifedipine ER
* Inability or unwillingness to provide informed consent
* Already taking long-acting antihypertensive medication for standard care
* Maternal conditions that impact study outcomes: sickle cell disease, systemic lupus erythematosus
Study design
Enrollment target: 618 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-10-23
Estimated completion: 2029-06-30
Last updated: 2025-05-11
Interventions
Drug: Nifedipine ER
Primary outcomes
- • Chronic hypertension (One year postpartum)
Sponsor
Medical College of Wisconsin · other
With: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contacts & investigators
ContactAlyssa M Hernandez, DO · contact · alyhernandez@mcw.edu · 4148055285
ContactAmandla Stanley, MSN · contact · akstanley@mcw.edu · 4148056691
InvestigatorAnna Palatnik, MD · principal_investigator, Medical College of Wisconsin
All locations (2)
Northwestern UniversityRecruiting
Chicago, Illinois, United States
Medical College of WisconsinRecruiting
Milwaukee, Wisconsin, United States